Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

3153 CNS - nat > ic14 pharmacology of parkinsons, dementia > Flashcards

ic14 pharmacology of parkinsons, dementia Flashcards

1
Q

What are the cardinal signs of Parkinsons disease

A

TRA)
1) Tremors at rest (pill rolling)
2) Rigidity
Cogwheel rigidity
3) Akinesia / Bradykinesia
Slowness of movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference between the cause of Parkinsons disease and EPSE

A

Parkinsons disease: dopamine deficiency due to neuronal degeneration

EPSE: dopamine deficiency due to dopamine blockade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pathology of parkinsons disease

A

Impaired clearing of abnormal / damaged intracellular proteins by ubiquitin-proteosomal system

Misfolded alpha-synuclein proteins aggregate to form fibrils, fibrils aggregate to form Lewy body

Results in accumulations of aggresomes or Lewy bodies in the basal ganglia, causing:

Decrease in Dopamine neurotransmission
Mitochondrial failure

Degeneration of dopaminergic neurons with Lewy body inclusions in substantia nigra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Function of basal ganglia

A

Contains substantia nigra

Involved in action selection
AKA brain is telling body to move in many different directions but Substantia Nigra sends a dopamine signal to only select one action and inhibits the rest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the dopamine subtypes in the nigrostriatum? What is the nature of the neuronal pathway?

A

Excitatory D1 and inhibitory D2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What happens when the substantia nigra is damaged

A

Loss of Substantia Nigra → no release of inhibition → hypokinetic state

Usually Substantia Nigra will release inhibition of one action and hence can carry out one action, but now all actions are inhibited and patient becomes hypokinetic, moves slowly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is dopamine produced?

A

L-tyrosine → L-dopa
By tyrosine hydroxylase

L-dopa → Dopamine
By DOPA decarboxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is dopamine broken down?

A

By COMT and MAO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Between L-dopa and Dopamine, which one pass through BBB?

A

L-dopa passes through BBB
So that L-dopa can be synthesised into Dopamine

Dopamine does not pass through BBB
Hence no point making Dopamine elsewhere apart from the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the drugs to treat parkinsons and their MOA? (6 points)

A

1) Levodopa benserazide + carbidopa
2) COMTi (Entacapone, Tocapone)
3) MAOi
4) Dopamine receptor agonist (Pramipexole, Pergolide, Ropinirole)
5) Amantadine (NMDA antagonist)
6) Benzhexol / Trihexyphenidyl (anticholinergic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Levodopa paired with? What is the MOA?

A

Carbidopa / Benserazide

Peripherally DOPA-decarboxylase inhibitor
Prevent L-dopa from converting to Dopamine in other parts of the body other than the brain and causing side effects

“Since DOPA-decarboxylase blocks conversion of L-dopa to Dopamine, if i block DOPA-decarboxylase in other sites, more L-dopa retained and not converted to Dopamine, more L-dopa can pass through BBB and enter brain + lesser peripheral Dopamine causing side effects”

Allows for lower dose of L-dopa also

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the bioavailability of Levodopa? What is absorption affected by?

A

Bioavailability
33% for Levodopa, 75% with benserazide or cabidopa

Absorption decreased with high fat or protein meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Side effects of Levodopa, short term (4 points) and long term (3 points)

A

Short term:
nausea, vomiting
postural hypotension
Sudden sleep onset
Hallucination, psychosis

Long term:
Wearing off
Peak dose dyskinesia
On off phenomenon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How to resolve motor complications of Levodopa

A

Wearing off
Between 8am to 2pm dose, effect of Levodopa wears off before the next dose
Can reduce dosing interval eg. TDS → QDS
Replace with modified release preparations eg. Madopar HBS

Peak dose dyskinesia
Can occur at the peak dose, 1-2hrs after taking dose
Increase dosing frequency but maintain total dose → Peak will be lower

On Off” phenomenon
Unpredictable, not related to dosing interval
Late stage of disease, taking Levodopa for very long already
Can offer Amantadine which may help with dyskinesia

General: Offer adjunctive treatment eg. Dopamine agonist, MAOi, COMTi, Amantadine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Counselling points of Levodopa

A

Take with empty stomach or snacks, do not take with high protein or fat meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MOA and example of COMT inhibitors

A

Entacapone, Tolcapone

MOA
Block Dopamine and L-DOPA breakdown by inhibiting COMT
More Levodopa available to enter brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which drug should be administered with Levodopa

A

COMTi, should not be monotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Formulations of COMTi and benefits

A

Exist in combination with Levodopa + Carbidopa

Good for patients with swallowing difficulties but cannot be titrated individually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Side effects of COMTi (6 points)

A

Increase dyskinesia (abnormal movement) upon initiation
Liver dysfunction (Tolcapone)
Nausea, diarrhea
Urinary discoloration
Visual hallucination
Drowsiness, sleep disturbances

20
Q

Drug food / drug interactions with COMTi (2 points)

A

Iron, Calcium

MAO-A inhibitors eg. Moclobemide

21
Q

What drugs interact with iron

A

Levodopa, COMTi (Entacapone)

22
Q

Examples of MAOi used for parkinsons

What is the indication?

A

MAO-B selective
Selegiline, Rasagiline

For mild parkinsons
Can try before Levodopa
Can be used as monotherapy

23
Q

What is a side effect of Selegiline? How does it occur?

A

Insomnia, Selegiline hepatically metabolised to amphetamines, very stimulating
BD second dose should be taken earlier, so patient can fall asleep
Not for Rasagiline as it is not metabolised to amphetamines

24
Q

Drug food interaction with Selegiline, Rasagiline

A

Tyramine rich food eg. cheese

25
Q

Ergot dopamine antagonists (3 points)

Non-ergot dopamine antagonists (4 points)

A

Ergot derivatives
Pergolide
Cabergoline
Bromocriptine

Non-ergot derivatives
Ropinirole
Pramipexole
Rotigotine (transdermal)
Apomorphine (SC)

26
Q

Indication of dopamine agonists

A

Adjunct or monotherapy
Can reduce dose or delay use of Levodopa
Young patients
If start young patients on Levodopa, they will eventually get dyskinesia

27
Q

What medications should be started for mild parkinsons or young parkinsons patients?

A

1) MAO B inhibitors eg. Selegiline

2) Dopamine receptor agonist eg. Pramipexole, Pergolide, Ropinirole

Levodopa not suitable cos patients will get dyskinesia eventually, want to delay use
COMT need to use with Levodopa
Amantadine is more for reducing dyskinesia
Anticholinergics used to control tremors

28
Q

What are some side effects of ergot derivatives

A

Peritoneal fibrosis, cardiac valve regurgitation

29
Q

Peripheral dopaminergic side effects

Central dopaminergic side effects

A

Peripheral = legs, head
Nausea, vomiting
Orthostatic hypotension
Leg oedema

Central = brain
Hallucinations
Drowsiness
Compulsive behaviors
Must counsel for newly started patients
Gambling, shopping, eating

30
Q

Important counselling point for Dopamine agonist

A

Compulsive behavior eg. Gambling, shopping, eating

31
Q

Which has longer bioavailability, ergot or non ergot DA

A

ergot has lower bioF

32
Q

Which dopamine agonist need dose adjustment in renal impairment

A

Pramipexole

33
Q

MOA of Amantadine (6 points)

A

1) NMDA receptor antagonist
Glutamate bind to NMDA receptors, cause excitation
Higher glutamatergic activity → lead to Levodopa induced dyskinesia

2) Dopamine reuptake inhibitor

3) Release stored dopamine

4) Dopamine receptor agonist

5) Upregulate D2 receptors

6) Anticholinergic

34
Q

How is Amantadine excreted

When should second dose be taken

A

Renally

In the afternoon, very stimulating (like Bupropion and Selegiline)

35
Q

What drugs are stimulating, and what to do?

A

Bupropion, Selegiline, Amantadine

Bupropion and selegiline metabolised to amphetamine like molecules

Dose in afternoon

36
Q

Side effect of Amantadine

A

Livedo reticularis
Net-like pattern, reddish blue discoloration

37
Q

Why are anticholinergics used in Parkinsons?

A

controlling tremors in PD
Treat sialorrhea (hypersalivation)

38
Q

What is dementia caused by?

A

1) Senile plaques
Amyloid Precursor Protein (APP) cleaved by secretase to form Beta - amyloid peptides
Senile plaques are aggregates of Beta-amyloid (AB) peptide

2) Neurofibrillary tangles
1) Tau protein is needed for intracellular transport in neurons
2) When Tau protein phosphorylate by kinases, they aggregate to form PHF (paired helical filaments)
3) No intracellular transport in the neuronal cell, causing neurons to degenerate

Result in degeneration of the central cholinergic system and hippocampus

39
Q

Drugs to treat dementia

A

1) Acetylcholinesterase inhibitors aka Cholinergics
Donepezil, Galantamine, Rivastigmine

2) Memantine (NMDA antagonist)

40
Q

Indication and Examples of AChEi (3 points)

A

For mild to moderate dementia
Slow titration dosing regimen over 4-8 weeks

Donepezil (also for severe)
Galantamine
Rivastigmine

41
Q

Similarity and differences between Galantamine and Rivastigmine (4 points)

A

Dosage form
Rivastigmine: oral and transdermal
Galantamine: oral only

Half life
Rivastigmine has shorter half life (hence need transdermal patch)

Additional MOA
Galantamine act on nicotinic receptors in brain, contributing to therapeutic effect

Metabolism
Galantamine: liver CYP450
Rivastigmine: kidneys

42
Q

Side effects of AChEi

A

Cholinergic activation (opposite of anticholinergic)
Nausea, vomiting
Diarrhea (opposite of constipation)
Muscle cramp
Bradycardia (opposite of tachycardia in anticholinergics)
Loss of appetite
Increased gastric juice secretion

43
Q

Who are contraindicated with AChEi

caution in use

A

CI: Patients on beta blockers, bradycardia

Caution: Patients with PUD, respiratory disease, seizures, urinary tract obstruction

44
Q

Indication of Memantine

A

For moderate to severe disease

45
Q

MOA of memantine

A

Non-competitive NMDA receptor antagonist
NMDA is a Glutamate receptor, Glutamate is the main excitatory neurotransmitter
Glutamate binds to NMDA, causing overstimulating various glutamate receptors and leading to excitotoxicity and neuronal cell death, contributing to AD → hence need to block NMDA receptor

46
Q

Side effects of Memantine

A

Hallucination
Confusion
Dizziness
Headache

3153 CNS - nat (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions